Form 4: Jazz Pharmaceuticals Director Patrick Kennedy Reports Acquisition of Common Stock

Director Patrick Kennedy reports acquiring 1,423 shares of Jazz Pharmaceuticals common stock on March 1, 2024, through restricted stock units.

Summary

• On March 1, 2024, Patrick Kennedy, a director of Jazz Pharmaceuticals plc, acquired 1,423 shares of common stock.
• The acquisition was made through restricted stock units granted under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• Each restricted stock unit represents a contingent right to receive one ordinary share upon vesting.
• The restricted stock units will vest in full on August 3, 2024, subject to continuous service and certain additional conditions.
• Following the transaction, Mr. Kennedy beneficially owns 1,423 shares of Jazz Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock acquisition by a director. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units will vest on August 3, 2024, subject to the Reporting Person's continuous service and certain additional conditions.

Industry Context

This filing is a routine disclosure related to stock-based compensation for a company director, which is a common practice in publicly traded companies to align the interests of management and shareholders.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates